Brief: Valneva's Cash, Cash Equivalents At EUR 143.5 Mln At End-September
20/11/2025 06:02
Nov 20 (Reuters) - Valneva SE VLS.PA: 9M ADJUSTED EBITDA EUR -37.7 MILLION 9M NET INCOME EUR -65.2 MILLION 9M REVENUE EUR 127 MILLION FULL-YEAR 2025 FINANCIAL GUIDANCE REITERATRED CASH AND CASH EQUIVALENTS WERE EUR 143.5 MILLION AS AT SEPTEMBER 30, 2025 Source text: ID:nGNE7H805p Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency